ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Nitrofuran drugs >Nitrofurantoin

Nitrofurantoin

Nitrofurantoin Suppliers list
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Nitrofurantoin
CAS:67-20-9
Purity:99.00% Package:100g,500g,1KG,10KG,100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:67-20-9
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Email: sale@mainchem.com
Products Intro: Product Name:Nitrofurantoin
CAS:67-20-9
Company Name: Shanghai Yingrui Biopharma Co., Ltd.
Tel: +86-21-33585366 E-mail:sales03@shyrchem.com
Email: sales03@shyrchem.com
Products Intro: Product Name:Nitrofurantoin
CAS:67-20-9
Purity:0.98 Package:100g;250g;500g;1kg
Company Name: Shanghai Zheyan Biotech Co., Ltd.
Tel: 18017610038
Email: zheyansh@163.com
Products Intro: Product Name:Nitrofurantoin
CAS:67-20-9
Purity:HPLC>=98% Package:250mg

Lastest Price from Nitrofurantoin manufacturers

  • Nitrofurantoin
  • US $1.00 / Kg/Drum
  • 2019-10-29
  • CAS:67-20-9
  • Min. Order: 25Kg/Drum
  • Purity: 98%
  • Supply Ability: 1ton
  • Nitrofurantoin
  • US $7.00 / kg
  • 2019-07-06
  • CAS:67-20-9
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 10000kg
Nitrofurantoin Basic information
Introduction Medical use Pharmacology and microbiology Production Side effects Reference
Product Name:Nitrofurantoin
Synonyms:1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione;1-(5-NITRO-2-FURFURYLIDENEAMINO)HYDANTOIN;1-[(5-nitrofurfurylidene)amino]hydantoin;LABOTEST-BB LT00134625;FURADOXYL;N-(5-NITRO-2-FURFURYLIDENE)-1-AMINOHYDANTOIN;NITROFURANTOIN;NITROFURANTOINE
CAS:67-20-9
MF:C8H6N4O5
MW:238.16
EINECS:200-646-5
Product Categories:-;Furan&Benzofuran;Peptide Synthesis/Antibiotics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;antibiotic
Mol File:67-20-9.mol
Nitrofurantoin Structure
Nitrofurantoin Chemical Properties
Melting point 268°C
Boiling point 380.75°C (rough estimate)
density 1.5824 (rough estimate)
refractive index 1.6700 (estimate)
storage temp. 0-6°C
solubility DMF: soluble50mg/mL
pka7.2(at 25℃)
form crystalline
color yellow
Water Solubility <0.01 g/100 mL at 19 ºC
Sensitive Light Sensitive & Hygroscopic
λmax358nm(MeOH)(lit.)
Merck 14,6599
BRN 893207
Stability:Stability Stable, but light-sensitive. Combustible. Incompatible with strong oxidizing agents, strong alkalies, strong acids. Decomposes upon contact with most metals other than stainless steel and aluminium.
CAS DataBase Reference67-20-9(CAS DataBase Reference)
NIST Chemistry ReferenceHydantoin, n-(5-nitro-2-furfurylidene)-1-amino-(67-20-9)
EPA Substance Registry System2,4-Imidazolidinedione, 1-[[(5-nitro-2-furanyl)methylene] amino]-(67-20-9)
Safety Information
Hazard Codes Xn
Risk Statements 22-42/43
Safety Statements 22-36/37-45
RIDADR 2811
WGK Germany 3
RTECS MU2800000
TSCA Yes
HazardClass 6.1(b)
PackingGroup III
HS Code 29349990
Hazardous Substances Data67-20-9(Hazardous Substances Data)
ToxicityLD50 oral in rat: 604mg/kg
MSDS Information
ProviderLanguage
Nitrofurantoin English
SigmaAldrich English
ALFA English
Nitrofurantoin Usage And Synthesis
IntroductionNitrofurantoin, (Furadantin, or N-(5-nitro-2-furfurylidene)-l-amino-hydantoin), is an antibiotic agent that fights bacteria in the body. Nitrofurantoin is a yellow, crystal-line compound of bitter taste, which darkens on exposure to light or alkali1. This antibiotic is commonly used to treat urinary tract infections. It is also extensively used in prophylaxis of uncomplicated lower urinary-tract infections2. Nitrofurantoin has been used since 1950s and it is a well-known and studied drug with limited antibiotic resistance3.
Medical useThe oral dose of nitrofurantoin for adults is usually 50-100 mg, four times daily, with meals and at bedtime. Treatment of this medicine is usually continued for 14 days. The daily dose for children is 5-7 mg/kg, given in four divided oral doses. The dosage should be reduced if continued beyond 14 days or if used for prophylaxis. For long-term treatments, an oral dose of 1 mg/kg is recommended4.
Pharmacology and microbiologyNitrofurantoin has a wide range of antimicrobial activity against both Gram negative and positive organisms. Its bacteriostatic effect can be achieved at a concentration of 32 pg/ml especially in an acidic urine5. The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. The nitro group coupled in the heterocyclic furan ring represents the specific active site of the drug and once activated by microbial nitro-reductases is able to interfere with protein and DNA synthesis, thus impairing energy metabolism, cell wall and carbohydrate synthesis. The broad-based nature of this action may explain the lack of acquired bacterial resistance to nitrofurantoin, as the necessary multiple and simultaneous mutations of the target macromolecules would likely be lethal to the bacteria 6. Nitrofurantoin is highly effective against E. coli, Enterococci, Aerobacter, and Staphylococcus saprophyticus infections, but less effective against Streptococcus, Proteus and Pseudornonas Serratia species7, 8.
From a pharmacokinetic point of view, the bioavailability of nitrofurantoin is about 90%. However, the plasma concentrations are very low, which is lower than 1 mg/L after an oral dose of 100 mg. The elimination half-life is short, which is around 1 h, and 27–50% of the nitrofurantoin drug is excreted unchanged in the urine. Even though peak urinary levels might be higher than 100 mg/L (range 50–200 mg/L), these are maintained for a relatively short time. Thus, nitrofurantoin should be avoided in patients with moderate to severe renal failure (creatinine clearance <50 mL/min)9.
ProductionNitrofurantoin is not known to occur naturally. It can be prepared from 1-aminohydantoin sulfate or hydrochloride and 5-nitro-2-furaldehyde diacetate in isopropyl alcohol media10.
Side effectsThe common side effects of nitrofurantoin happen in more than 1 in 100 people. Nitrofurantoin may cause the patients’ urine turn into dark yellow or a brownish color. This symptom is normal and will disappear after stopping taking nitrofurantoin. Mild side effects of nitrofurantoin include feeling sick and vomiting, diarrhea, loss of appetite, headaches, dizziness or feeling sleepy. Serious side effects are rare and happen in less than 1 in 1,000 people. Those symptoms include but not limited to chest pains, difficulty in breathing, coughing, chills, or a high temperature, yellowing of the skin or eyes, tingling sensations, bleeding and bad headache. In emergency cases, it is also possible to have a serious allergic reaction to nitrofurantoin11.
Nitrofurantoin is classified in FDA pregnancy category B. It is not expected to be harmful to an unborn baby during early pregnancy 5, but it is not recommended for the last 2-4 weeks of pregnancy. Nitrofurantoin can pass into breast milk and may harm a nursing baby12. Nitrofurantoin should not be given to a child younger than 1 month old and patients having severe kidney diseases, urination problems or a history of jaundice or liver problems caused by nitrofurantoin13.
Hepatic injury after both acute and chronic exposure to nitrofurantoin has been reported. Long-term exposure to nitrofurantoin may cause chronic active hepatitis14.
Adverse reactions related to using nitrofurantoin in children reported in the literature are gastrointestinal disturbance, cutaneous reactions, pulmonary toxicity, hepatoxicity, hematological toxicity, neurotoxicity and an increased rate of sister chromatid exchanges. However, the use of nitrofurantoin is safe in children for long-term prophylactic therapy. Adverse reactions exist but they are less common than seen in adults, presumably because of the lower dose used for therapy, and the lack of significant comorbidities and drug interactions in children15.
Other side effects of nitrofurantoin have been associated with neurotoxicity (including peripheral neuropathy, dizziness, vertigo, diplopia, and cerebellar dysfunction) and benign intracranial hypertension. Those mentioned side effects are most prevalent in women and elderly patients, and their pathogenesis is hypothesized to be due to axon loss16.
Reference
  1. H.B. Hasen, T.D. Moore, Nitrofurantoin: a study in vitro and in vivo in one hundred cases of urinary infection, Journal of the American Medical Association, 155(1954) 1470-3.
  2. A. Huttner, E.M. Verhaegh, S. Harbarth, A.E. Muller, U. Theuretzbacher, J.W. Mouton, Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials, Journal of Antimicrobial Chemotherapy, 70(2015) 2456-64.
  3. J.R. Price, L.A. Guran, W.T. Gregory, M.S. McDonagh, Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis, American journal of obstetrics and gynecology, 215(2016) 548-60.
  4. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono50-15.pdf
  5. S.B. David, T. Einarson, Y.B. David, I. Nulman, A. Pastuszak, G. Koren, The safety of nitrofurantoin during the first trimester of pregnancy: meta‐analysis, Fundamental & clinical pharmacology, 9(1995) 503-7.
  6. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020064s019lbl.pdf
  7. J.A. McKinnnel, L.G. Miller, Nitrofurantoin: Preferred Empiric Therapy for Community-Acquired Lower Urinary Tract Infections: In Response, Mayo Clinic Proceedings, Elsevier2011, p. 1244.
  8. D. Kyabaggu, F. Ejobi, D. Olila, The sensitivities to first-line antibiotic therapy of the common urinary tract bacterial infections detected in urine samples at a hospital in metropolitan Kampala (Uganda), African health sciences, 7(2007).
  9. A. Novelli, E. Rosi, Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections, Journal of Chemotherapy, 29(2017) 10-8.
  10. https://monographs.iarc.fr/wp-content/uploads/2018/06/mono50-15.pdf
  11. https://beta.nhs.uk/medicines/nitrofurantoin/
  12. P.M. Gerk, R.J. Kuhn, N.S. Desai, P.J. McNamara, Active transport of nitrofurantoin into human milk, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 21(2001) 669-75.
  13. https://www.sciencedaily.com/releases/2015/04/150427124627.htm
  14. G. Amit, P. Cohen, Z. Ackerman, Nitrofurantoin-induced chronic active hepatitis, IMAJ-RAMAT GAN-, 4(2002) 184-6.
  15. E. Karpman, E.A. Kurzrock, Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children, The Journal of urology, 172(2004) 448-53.
  16. A. Mattappalil, K.A. Mergenhagen, Neurotoxicity with antimicrobials in the elderly: a review, Clinical therapeutics, 36(2014) 1489-511. e4.
Chemical Propertieslemon yellow crystalline powder
Usescounterirritant
UsesA nitrofuran antibiotic with low resistance potential that is rapidly metabolized by mammals. Active against both Gram-positive and Gram-negative bacteria. Nitrofurantoin is also a prooxidant that is cytotoxic due to the generation of intracellular H2O2. Antibacterial.
DefinitionChEBI: An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.
Brand nameIvadantin (Procter & Gamble);Furan;Nitrofan.
Antimicrobial activityIt is active against almost all the common urinary pathogens, except Proteus mirabilis. It is bactericidal.
It antagonizes the activity of nalidixic acid and other quinolones in vitro, but this combination is unlikely to be used clinically.
Acquired resistanceSurprisingly for an agent that has been used for so long, resistance remains uncommon. R-factor-mediated resistance has been reported, but this appears to be very unusual. The mechanism of resistance seems to be a decreased nitroreductase activity in the target organism.
There is cross-resistance within the nitrofuran group, but none with antibiotics of other chemical classes.
General DescriptionOdorless lemon yellow crystals or fine yellow powder. Bitter taste.
Air & Water ReactionsInsoluble in water.
Reactivity ProfileNitrofurantoin is sensitive to light. Nitrofurantoin is incompatible with alkalis. Nitrofurantoin is also incompatible with strong oxidizers and strong acids. Nitrofurantoin decomposes on contact with metals other than stainless steel and aluminum.
HazardQuestionable carcinogen.
Fire HazardFlash point data for Nitrofurantoin are not available; however, Nitrofurantoin is probably combustible.
Pharmaceutical ApplicationsA synthetic compound available only for oral administration. There are three formulations, differing in their crystalline nature: microcrystalline, macrocrystalline, and a delayedrelease preparation containing a combination of the two. The macrocrystalline form is said to be less liable to give rise to the most common adverse event, nausea. However, pharmacokinetic and clinical trial evidence for this assertion is not very strong.
It is slightly soluble in water (c. 200 mg/L) but more so in dilute alkali. Solubility in ethanol is modest (500 mg/L), but the compound dissolves very well in dimethylformamide (80 g/L). If packaged in light-resistant containers and kept at room temperature, it is stable for more than 5 years. The yellow solution should be kept in the dark.
PharmacokineticsOral absorption:>95%
Cmax 100 mg oral: <2 mg/L after 1–4 h
Plasma half-life:0.5–1 h
Volume of distribution: 0.6 L/kg
Plasma protein binding: 60–70%
Absorption
It is absorbed mainly from the proximal small intestine and the plasma peak concentration may not be achieved for as long as 4 h. The recommendation to take the drug with food may be motivated by reducing the incidence of nausea rather than increasing bioavailability.
Bioavailability varies widely between different brands and this may not be apparent from results of standard in-vitro pharmaceutical tests. Therefore, different brands should not be substituted unless therapeutic equivalence has been formally established.
Distribution
Serum levels are low, owing to extensive metabolism and the short plasma half-life. Tissue concentrations are too low for adequate treatment of systemic infection, including pyelonephritis. Negligible concentrations are found in breast milk and only a small amount crosses the placenta.
Metabolism and excretion
About 20% of the dose is excreted in microbiologically active form in the urine, sufficient to give inhibitory concentrations against urinary pathogens for up to 6 h. With reduced renal function (creatinine clearance <60 mL/min), urinary excretion falls, and virtually ceases when creatinine clearance is below 20 mL/min. This gives rise to the risk of accumulation in the blood and inadequate urine levels. With this proviso, it can be given to elderly patients. Infants over the age of 3 months may also be treated, but in the absence of a suitable suspension, and at the recommended dosage, a 6-month baby would need to be given one-tenth of a standard 50 mg tablet.
Clinical UseAcute dysuria and frequency
Bacteriuria in pregnancy
Prophylaxis of recurrent cystitis (reduced dosage)
Side effectsNausea, which may be combined with anorexia or vomiting, or both, occurs in about 30% of patients taking the microcrystalline form, causing about 10% to stop treatment. The frequency of nausea is approximately halved with the macrocrystalline formulation. Nausea is due to a direct effect on the vomiting center; it occurs early in the course, and its incidence may be reduced by taking the medication with food or milk.
Pulmonary, hepatic, neurological and hematological side effects have been reported, but are very uncommon. There are two kinds of pulmonary reaction. Acute reactions are the more common, starting within 5–10 days of the first dose, or within a few hours on re-challenge. Symptoms may resemble those found in asthma, tracheobronchitis or pneumonia, and usually resolve permanently within 2 days. There may be an eosinophilia. Subacute or chronic reactions, often referred to as pneumonitis, are of more gradual onset, and resolve only slowly when the drug is stopped. Prolonged dyspnea and cough may be accompanied by fibrosis.
Hepatic reactions follow prolonged drug usage and usually manifest as chronic active hepatitis, sometimes with cirrhosis. The prognosis is good, but recovery may take months. Peripheral neuropathy has been reported mainly in patients with pre-existing impaired renal function. The prognosis depends upon the severity of the symptoms. Unlike hepatic and pulmonary effects, for which immunological phenomena seem to be responsible, neurological events have been attributed to a direct toxic effect of the drug, one of its metabolites or the superoxide generated in vivo.
In common with other nitrofurans, nitrofurantoin may cause hemolysis in patients who lack glucose-6-phosphate dehydrogenase.
Safety ProfilePoison by ingestion and intraperitoneal routes. Human systemic effects: peripheral motor nerve recording changes, ataxia, changes in urine composition, and hemolysis with or without anemia. Human reproductive effects by ingestion: spermatogenesis. An experimental teratogen. Other experimental reproductive effects. Questionable carcinogen with experimental neoplastigenic data. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx.
Veterinary Drugs and TreatmentsConsidered a urinary tract antiseptic, nitrofurantoin is used primarily in small animals, but also occasionally in horses in the treatment of lower urinary tract infections caused by susceptible bacteria. It is not effective in treating renal cortical or perinephric abscesses or other systemic infections.
Nitrofurantoin Preparation Products And Raw materials
Raw materialsAcetone-->Hydrazinium hydroxide-->Ethyl chloroacetate-->Furfural-->Semicarbazide-->5-Nitro-2-furaldehyde diacetate
Tag:Nitrofurantoin(67-20-9) Related Product Information
Levofloxacin HCL Capsule Ciprofloxacin hydrochloride Furan FU 1-AMINOHYDANTOIN 2-NP-AMOZ NITROFURANTOIN RELATED COMPOUND A (25 MG) (N-(AMINOCARBONYL)-N-[([5-NITRO-2-FURANYL]-METHY- LENE)-AMINO]-GLYCINE) 1-AMINO-IMIDAZOLIDIN-2,4-DIONE NITROFURANTOIN, SODIUM SALT,nitrofurantoin sodium 1-AMINO-IMIDAZOLIDIN-2,4-DIONE (AHD) 3-AMINO-5-MORPHOLIN-4-YLMETHYL-OXAZOLIDIN-2-ONE-D5 NITROFURANTOIN RELATED COMPOUND A (25 MG) (N-(AMINOCARBONYL)-N-[([5-NITRO-2-FURANYL]-METHY-LENE)-AMINO]-GLYCINE) nifurfoline Nitrofurantoin Nitrofurantoin1-Hydrate,Nitrofurantoin monohydrate nifurtoinol